COMMENTARY

Generating evidence for diagnosis and therapy of RarE LiVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses

Juri Fuchs1†, Anastasia Murtha-Lemekhova1†, Jan Pfeifferberger2, Alexander Fichtner3, Patrick Günther4, Niels Halama5,6, Philipp Mayer7, Daniel Hornuss8, Rosa Klotz1,9, Pascal Probst1,9, Katrin Hoffmann1* and for the RELIVE Initiative

Abstract

Background: Rare liver lesions and diseases have seldomly aroused major interest of researchers. For most guidelines, presumably similar clinical conditions are pooled without detailed investigations of singularities that they present.

Main text: A multidisciplinary project aiming to establish evidence-based therapies for rare liver diseases has been founded. A series of systematic reviews and meta-analyses will be the starting point for a structured development of guidelines for rare conditions of the liver affecting pediatric and adult populations. The novel approach will be focusing on case reports and small patient series with distinct rare liver diseases without pooling several presumably acceptably similar conditions. Thus, a vital resource of information will be utilized, which has been largely neglected hitherto.

Conclusion: Highly specific recommendations based on highest available evidence will therefore be developed for specific conditions, advancing the individualized medicine approach for the afflicted patients.

Keywords: Rare liver disease, Rare liver tumors, Evidence-based medicine, Systematic reviews, Meta-analysis, RELIVE

Background

Generating evidence for rare diseases based on clinical studies is, inevitably, difficult. As a consequence, the diagnostic and therapeutic approaches for many rare conditions rely primarily on individual experiences or guidelines developed for allegedly similar but more common diseases. Yet, the assumption of clinically relevant similarity is often unsubstantiated. This means that, frequently, current treatment recommendations for patients with rare diseases are based on the lowest level of scientific evidence [1]. The heterogeneous group of rare liver diseases and tumors is particularly affected by this shortcoming [2]. Specifically, the impact of surgical therapies and different operative techniques remains yet to be investigated. For the pediatric population, the situation is even more complex as patient numbers are lower, the reporting and publication bias of cases are high, and the implementation of clinical trials has additional ethical implications and constraints.

†Juri Fuchs and Anastasia Murtha-Lemekhova share first authorship
*Correspondence: katrin.hoffmann@med.uni-heidelberg.de
1 Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reviewing the literature on various rare liver diseases, a considerable amount of case reports and small case series can be found. A few patient series from multi-institutional study registries tend to be the highest level of evidence available for most diseases, with virtually all data being retrospective. Long-term observational studies including large sample sizes are lacking, and randomized controlled trials are practically non-existent. Conducting such trials is hampered by the complexity of organizing multi-institutional and international studies, and, understandably, by the low number of eligible patients and necessity of a long study duration. So far, most studies have specifically excluded case reports and smaller series from their analyses. While there are some risks and obstacles to overcome when including case reports in reviews, they present a vital resource of information and can function as a base for generating evidence. Especially for very rare diseases, these reports are invaluable as many are only sufficiently described in case reports or series and are lacking true single entity cohort studies. Important data is lost when case reports and series are systematically ruled out. We argue that the dogma of categorically excluding smaller studies from systematic reviews and meta-analyses is unjustified. The informational benefit of these studies outweighs case report specific biases, provided certain methodological and statistical principles are applied. On the contrary, case reports often supply detailed data, and statistically robust results can be achieved, when larger number of individual cases is accumulated and analyzed.

**Structure and aim of RELIVE**

Researchers from seven medical disciplines form the RELIVE consortium, including experienced physicians, senior and junior scientists in the fields of hepatobiliary surgery, hepatology, pediatric hepatology, pediatric surgery, oncology, infectious diseases, and radiology. Thus, diseases and research questions will be viewed from different angles, providing for comprehensive and objective study results.

In light of the lack of evidence for rare liver diseases, we founded the RELIVE Initiative (RarE LIVER Disease Initiative). The aim of RELIVE is to raise awareness of rare liver lesions and conditions and to launch a collective effort for a better understanding, diagnosis, and treatment of uncommon liver diseases. For the RELIVE Initiative, we define rare liver diseases as all conditions that affect no more than one person in 2000. The focus will be set on disease with a particular lack of evidence concerning diagnosis and treatment, with all kinds of liver conditions, be it hereditary cholestatic, metabolic hepatic diseases or benign and malignant liver tumors of anatomical malformations. Researchers are motivated to write more reports and carry out studies on rare diseases despite the low number of cases. To generate higher evidence, we intend to launch a series of systematic reviews (SR) that will be predominantly based on small studies on specific lesions and afflictions of the liver in adult and pediatric populations. The applied systematic approach will be a major step towards an evidence-based treatment of rare liver tumors and diseases. Although SRs and meta-analyses of small studies bear the risk of several biases, they will nevertheless provide the highest level of evidence available. We are convinced that this will lead to a better understanding of rare liver diseases and their therapy. Based on the results of the SRs and pooled data analyses, a better comparative analysis between similar conditions or variants of tumors can be made. Furthermore, RELIVE will allow for the development of clinical recommendations and research questions for future studies. Other methods such as prospective trials and translational studies can later be initiated within the framework of the RELIVE Initiative.

To ensure the highest study quality possible, a standardized systematic approach will be applied in all RELIVE systematic reviews. All systematic reviews and meta-analyses will be reported in accordance with the latest PRISMA guidelines [3, 4] and published in peer-reviewed open access journals. As provided in the PRISMA guidelines, study protocols will be drafted for all systematic reviews and registered in the international prospective register of systematic reviews, PROSPERO [5]. All included studies will be assessed for risk of bias; case reports will be evaluated based on the tool developed by Murad et al. [6]. For cohort studies of interventions or exposures, MINORS (methodological index for non-randomized studies) will be utilized [7]. In- and exclusion criteria for the study selection will be defined for each systematic review specifically adapted to the research questions. Deviation from this approach is possible only as a result of conclusive substantiations. In order to provide clear and reliable data, analyses will focus on summary statistics and univariate analyses. In-depth multivariate regression analyses or individual patient data analyses will be applied if sufficient raw data can be extracted from publications, providing statistically robust and sound results [8]. Meta-analyses or meta-regressions will only be conducted if appropriate. This means they will be used when comparative studies or several studies with larger cohorts are available [6]. To determine the certainty of evidence, the GRADE approach will be applied [9]. In order to avoid overestimation of the statistic effects found in our analyses, the interpretation will mainly focus on setting the data basis for developing clinical guidelines and for future prospective studies, instead of giving clinical directions or presenting supposedly
clear results. Inferences from these systematic reviews and meta-analyses can be used to guide decision-making in the clinical practice and will be the highest level of evidence for evaluated rare conditions.

**Conclusion**

Based on the RELIVE systematic reviews, robust recommendations on diagnostic and therapeutic approaches for rare liver diseases can be developed, solidified, or altered. Moreover, specific hypotheses can be derived, which can then be tested in future trials. The long-term goal of RELIVE is to engage the scientific community in developing targeted, evidence-based diagnostic and therapeutic guidelines for rare liver diseases and tumors.

**Abbreviations**

GRADE: Grading of Recommendations: Assessment, Development and Evaluation; MINORS: Methodological index for non-randomized studies; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RELIVE: Rare LIVEr Disease Initiative; SR: Systematic review.

**Acknowledgements**

Not applicable

**Authors’ contributions**

JF, conception, design, literature search, methodology, writing the manuscript, reviewing the manuscript, and approval of the submitted version. AML, conception, design, literature search, methodology, writing the manuscript, reviewing the manuscript, and approval of the submitted version. PP, conception, design, literature search, methodology, writing the manuscript, reviewing the manuscript, and approval of the submitted version. DH, conception, design, methodology, reviewing the manuscript, and approval of the submitted version. KH, conception, design, methodology, reviewing the manuscript, and approval of the submitted version. PG, conception, design, literature search, methodology, reviewing the manuscript, and approval of the submitted version. AF, conception, design, methodology, reviewing the manuscript, and approval of the submitted version. JP, conception, design, literature search, methodology, writing the manuscript, reviewing the manuscript, and approval of the submitted version. AML, conception, design, literature search, methodology, writing the manuscript, reviewing the manuscript, and approval of the submitted version. JF and AML equally contributed to the conception and development of the RELIVE initiative and share first authorship. The authors read and approved the final manuscript.

**Funding**

No funding in any form was received.

**Availability of data and materials**

Not applicable

**Declarations**

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany. 2. Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany. 3. Division of Pediatric Gastroenterology, Department of Pediatrics I, University Children’s Hospital Heidelberg, Heidelberg, Germany. 4. Division of Pediatric Surgery, Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany. 5. Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. 6. Division of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany. 8. Division of Infectious Diseases, Department of Medicine II, Medical Center — University of Freiburg, Freiburg im Breisgau, Germany. 9. Study Center of the German Surgical Society (SDGC), University of Heidelberg, Heidelberg, Germany.

**References**

1. Friebe T, Rover C, Wandel S, Neuschwander B. Meta-analysis of few small studies in orphan diseases. Res Synthesis Methods. 2017;8(1):79–91.
2. Jones DE, Sturm E, Lohse AW. Access to care in rare liver diseases: new challenges and new opportunities. J Hepatol. 2018;68(3):577–85.
3. Page MI, McKenzie IE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
4. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for a Systematic Review and Meta-Analysis of individual participant data: the PRISMA-IPD statement. Jama. 2015;313(16):1657–65.
5. www.crd.york.ac.uk/PROSPERO#aboutPage Accessed 17.09.2021
6. Murad MH, Sultán S, Haffar S, Bazerbach F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–3.
7. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(6):712–6.
8. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 2002;55(1):86–94.
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.